Genetic Technologies (GENE) Competitors $0.76 0.00 (0.00%) As of 04/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GENE vs. ME, SPRB, INAB, QNTM, SYBX, AFMD, MEIP, IMNN, CLDI, and ORGSShould you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include 23andMe (ME), Spruce Biosciences (SPRB), IN8bio (INAB), Quantum Biopharma (QNTM), Synlogic (SYBX), Affimed (AFMD), MEI Pharma (MEIP), Imunon (IMNN), Calidi Biotherapeutics (CLDI), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry. Genetic Technologies vs. 23andMe Spruce Biosciences IN8bio Quantum Biopharma Synlogic Affimed MEI Pharma Imunon Calidi Biotherapeutics Orgenesis Genetic Technologies (NASDAQ:GENE) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking. Is GENE or ME more profitable? Genetic Technologies has a net margin of 0.00% compared to 23andMe's net margin of -183.39%. Genetic Technologies' return on equity of 0.00% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets Genetic TechnologiesN/A N/A N/A 23andMe -183.39%-170.07%-62.13% Which has better earnings & valuation, GENE or ME? Genetic Technologies has higher earnings, but lower revenue than 23andMe. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenetic Technologies$7.66M0.44-$7.88MN/AN/A23andMe$208.78M0.06-$666.70M-$15.45-0.03 Do institutionals and insiders hold more shares of GENE or ME? 0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by company insiders. Comparatively, 26.3% of 23andMe shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, GENE or ME? Genetic Technologies has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Does the media favor GENE or ME? In the previous week, Genetic Technologies had 4 more articles in the media than 23andMe. MarketBeat recorded 10 mentions for Genetic Technologies and 6 mentions for 23andMe. 23andMe's average media sentiment score of 0.18 beat Genetic Technologies' score of -0.15 indicating that 23andMe is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genetic Technologies 0 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral 23andMe 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate GENE or ME? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genetic Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.0023andMe 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the MarketBeat Community believe in GENE or ME? Genetic Technologies received 149 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 55.33% of users gave Genetic Technologies an outperform vote while only 46.15% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformGenetic TechnologiesOutperform Votes16155.33% Underperform Votes13044.67% 23andMeOutperform Votes1246.15% Underperform Votes1453.85% SummaryGenetic Technologies beats 23andMe on 8 of the 14 factors compared between the two stocks. Get Genetic Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GENE vs. The Competition Export to ExcelMetricGenetic TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.37M$2.92B$5.47B$7.82BDividend YieldN/A1.91%5.43%4.29%P/E RatioN/A29.7522.3918.43Price / Sales0.44481.28391.41101.46Price / CashN/A168.6838.1834.62Price / Book3.063.036.684.19Net Income-$7.88M-$72.17M$3.22B$248.05M7 Day PerformanceN/A8.84%6.25%6.53%1 Month PerformanceN/A-4.01%-2.81%-2.16%1 Year Performance-66.59%-21.12%16.47%4.71% Genetic Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENEGenetic TechnologiesN/A$0.77flatN/AN/A$3.37M$7.66M0.0050Upcoming EarningsNews CoverageHigh Trading VolumeME23andMe0.4358 of 5 stars$0.50-35.3%$9.40+1,787.6%-94.6%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeSPRBSpruce Biosciences2.3171 of 5 stars$0.31+8.0%$2.50+695.2%-81.5%$12.99M$7.10M-0.3320Short Interest ↑Positive NewsGap UpINABIN8bio3.8211 of 5 stars$0.16+4.7%$6.00+3,668.8%-81.8%$12.94MN/A-0.2120Short Interest ↓Positive NewsQNTMQuantum BiopharmaN/A$6.72-3.2%N/AN/A$12.90MN/A-0.44N/APositive NewsSYBXSynlogic2.514 of 5 stars$1.10+7.3%N/A-39.7%$12.87M$8,000.00-0.2680Short Interest ↓Positive NewsGap DownAFMDAffimed3.4635 of 5 stars$0.79+27.2%$13.50+1,606.9%-80.8%$12.73M$877,000.000.00200Analyst ForecastMEIPMEI Pharma2.2911 of 5 stars$1.91+2.1%N/A-32.3%$12.73M$65.30M-0.33100Analyst ForecastShort Interest ↑News CoverageIMNNImunon2.3708 of 5 stars$0.87+2.4%$21.50+2,371.3%-39.1%$12.72M$500,000.00-0.4630Short Interest ↓CLDICalidi Biotherapeutics1.5641 of 5 stars$0.43-1.4%$15.00+3,357.0%N/A$12.35M$50,000.000.0038News CoverageORGSOrgenesisN/A$2.50+26.9%N/AN/A$12.00M$662,000.000.00150News Coverage Related Companies and Tools Related Companies ME Alternatives SPRB Alternatives INAB Alternatives QNTM Alternatives SYBX Alternatives AFMD Alternatives MEIP Alternatives IMNN Alternatives CLDI Alternatives ORGS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GENE) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genetic Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GENE Stock Free GENE Stock Alerts